Search company, investor...

Biodel

biodel.com

Founded Year

2003

Stage

Acq - P2P | Acquired

Total Raised

$21M

About Biodel

Biodel Inc. is a biopharmaceutical drug delivery company. Biodel develops drug delivery technologies that increase drug efficacy, enhance drug performance, and make drugs easier for patients to take. This technology is applicable to a wide range of peptides, proteins and other macromolecules. Using this technology, Biodel has developed a drug formulation of recombinant human insulin designed to speed the delivery of insulin into the blood called ViajectTM to treat patients with Type 1 and Type 2 diabetes. On May 17, 2007, Biodel had its initial public offering and now trades on Nasdaq under the symbol 'BIOD."

Headquarters Location

100 Saw Mill Road

Danbury, Connecticut, 06810,

United States

203-796-5000

Missing: Biodel's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Biodel's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Biodel

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Biodel in 1 CB Insights research brief, most recently on Oct 28, 2022.

Expert Collections containing Biodel

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biodel is included in 1 Expert Collection, including Diabetes.

D

Diabetes

2,051 items

Biodel Patents

Biodel has filed 14 patents.

The 3 most popular patent topics include:

  • Insecticides
  • Agricultural pest nematodes
  • Invasive plant species
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/9/2019

8/10/2021

Tylenchida, Invasive plant species, Agricultural pest nematodes, Insecticides, Plant physiology

Grant

Application Date

12/9/2019

Grant Date

8/10/2021

Title

Related Topics

Tylenchida, Invasive plant species, Agricultural pest nematodes, Insecticides, Plant physiology

Status

Grant

Latest Biodel News

Enanta Pharmaceuticals to Host Conference Call on August 7 at 430 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30 2017

Jul 25, 2017

Biodel to Report Third Quarter Fiscal Year 2011 Financial Results on August 4, 2011 Conference Call and Webcast Information To participate in the live conference call, please dial (855) 840-0595 in the U.S. or (518) 444-4814 for international callers. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on August 7, 2017, through 11:59 p.m. ET on August 10, 2017 by dialing (855) 859-2056 from the U.S. or (404) 537-3406 for international callers. The passcode for both the live call and the replay is 47670579. A live audio webcast of the call and replay can be accessed by visiting the “Events and Presentation” section on the “Investors” page of Enanta’s website at www.enanta.com . About Enanta Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta’s research and development efforts are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). Enanta has also discovered novel protease inhibitors that have been developed as part of AbbVie’s hepatitis C virus (HCV) treatment regimens under a collaboration that now provides Enanta a payment stream, which it is using to fund its research and development programs. Please visit www.enanta.com for more information on Enanta’s programs and pipeline. View source version on businesswire.com: http://www.businesswire.com/news/home/20170725005229/en/ Investor Contact

Biodel Frequently Asked Questions (FAQ)

  • When was Biodel founded?

    Biodel was founded in 2003.

  • Where is Biodel's headquarters?

    Biodel's headquarters is located at 100 Saw Mill Road, Danbury.

  • What is Biodel's latest funding round?

    Biodel's latest funding round is Acq - P2P.

  • How much did Biodel raise?

    Biodel raised a total of $21M.

  • Who are the investors of Biodel?

    Investors of Biodel include Albireo Pharma, Vivo Capital, Great Point Partners, UBS, New England Partners and 4 more.

  • Who are Biodel's competitors?

    Competitors of Biodel include Aphios, Array Biopharma, DiaMedica, PhaseBio Pharmaceuticals, CureDM and 15 more.

Compare Biodel to Competitors

R
Respirics

Respirics Inc. is a pulmonary drug delivery and development company located in Raleigh, North Carolina. The company is developing a line of branded inhalation drug products in its patented Acu-Breathe™ dry powder inhalers, and is working with pharmaceutical clients to enhance the delivery of their own compounds or formulations. Respirics combines proprietary inhalation technology with powder drug formulation expertise to develop unique drug delivery solutions. The company is committed to bringing effective, easy-to-use and affordable inhalation drug products to the patients who need them.

A
Adriacell

Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.

A
AM-Pharma

AM-Pharma is a biopharmaceutical company that focuses on the development of recombinant Alkaline Phosphatase for clinical use.

Oligomerix Logo
Oligomerix

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

W
Welgen

Welgen, Inc. is a biotech company developing technologies and products for biomedical research. The company was founded in 2002 to develop vectors for gene delivery and silencing that facilitate research activities in both academia and industry. The company's products provide the medical research community and the pharmaceutical industry with rapid and cost-efficient approaches for gene function research and drug development.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.